The Cancer Immunotherapy Armamentarium: Assessing Applications, Ambitions, and Amplitude by Corum, Natisha J.
University of North Dakota
UND Scholarly Commons
Essential Studies UNDergraduate Showcase Essential Studies Program
5-3-2018
The Cancer Immunotherapy Armamentarium:
Assessing Applications, Ambitions, and Amplitude
Natisha J. Corum
University of North Dakota
Follow this and additional works at: https://commons.und.edu/es-showcase
Part of the Medicine and Health Sciences Commons
This Poster is brought to you for free and open access by the Essential Studies Program at UND Scholarly Commons. It has been accepted for inclusion
in Essential Studies UNDergraduate Showcase by an authorized administrator of UND Scholarly Commons. For more information, please contact
zeineb.yousif@library.und.edu.
Recommended Citation
Corum, Natisha J., "The Cancer Immunotherapy Armamentarium: Assessing Applications, Ambitions, and Amplitude" (2018).
Essential Studies UNDergraduate Showcase. 9.
https://commons.und.edu/es-showcase/9
The cancer immunotherapy 
armamentarium: assessing 
applications, ambitions, and 
amplitude
----------Background----------
Etiology, progression, and prognosis varies from 
one cancer type to another, the commonality is the 
abnormal proliferation of cells leading to 
malignant neoplasia (Fig. 1) 
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Cancer is the second leading cause of 
death worldwide with a 70% increase in 
cases is expected over the next 20 years.1
Immunotherapy was recognized as 
advancement of the year in both 2016 and 
2017.2
Positive initial findings and clinical results 
of recent immunotherapies has 
precipitated a wave of attention and 
interest into the field, both in the general 
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To achieve this, it is imperative that research areas and therapeutic modalities are 
assessed for current and prospective functionality, applicability, and amplitude.
-----References-----
Two common targets: PD-L1 and CTLA4
A hallmark of cancers is their ability to suppress and/or 
evade the anti-tumor defenses of the immune system.5
Restoration and enhancement of immune function within 
the neoplastic microenvironment is thereby a logical and 
promising path to continue pursuing in the fight against 
cancer.
Essentially there are seven steps or points that must occur 
for the immune system to effectively kill cancer cells. (Fig. 2)
Others within the field think all the attention and support 
focused on immunotherapy can only be a good thing, and 
cultivates a landscape in which inquisition and competition leads 
to the best advances.4
The aspect agreed upon by both sides: more funding and support of 
cancer research is needed.
The importance of allocating funds and support sensibly is then critical.
Some experts have speculated that this influx of attention 
and focus on immunotherapies has gone too far.3
Only approved for treating 10 of 
over 100 cancer types6
Side effects/complications: 
autoimmune hepatitis, pneumonitis, 
pulmonary toxicity6
Oversaturation in clinical trials: 
currently over 1100 active trials3
Anticancer vaccines 
Anticancer vaccines use tumor antigen information, 
delivered via dendritic cell, peptide, or genetic 
vaccine to activate the patient’s immune system to 
fight cancer7
Relatively safe, lower incidence of serious side 
effects7
Problems: low affinity, response maintenance, 
mismatching, degradation, insertional mutagenesis7
Adoptive Cell Transfer (ACT)  
Tumor infiltrating lymphocyte (TIL), T cell receptor 
(TCR), and chimeric antigen receptor (CAR) are 
three  most common ACT therapies. (Fig. 5)
In TIL, lymphocytes are harvested from patient, the 
most effective are isolated, stimulated for growth to 
achieve therapeutic numbers, and then reinfused.9
In TCR and CAR, T-cells are harvested from the 
patient, engineered to highly express either a  ligand 
binding receptor or chimeric antigen receptor, 
expanded, and reintroduced to the patient.10
Challenges/limitations: immuno-depletion of 
already ill patients from cell harvesting, lack of 
persistence, antigen escape, and are difficult to 
produce with efficiency.10
Immunotherapy is a promising field in cancer research 
and treatment, but could likely never be an all-
encompassing savior in the fight against cancer. 
The challenge faced will be to work towards rational 
synergistic approaches with attainable applications and 
intelligent clinical designs. 
Interdisciplinary coordination and cooperation to 
appropriately allocate attention, funding, and further 
research  will remain imperative to be most successful in 
elucidating and developing the best arsenal against 
cancer. 
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Nanocarriers
Mechanogenetics
Epigenetic modulation Figure 1.  Normal cell division compared to cancerous proliferation.
14
Figure 2.  Cancer and the immune cycle.  CC: cancer cell.
DC: dendritic cell.  cTC: cytotoxic T cell.14
Figure 3.  Checkpoint inhibitors reinvigorate the immune system by 
preventing the binding and inhibition by cancer cells at specific surface 
targets. 14
Figure 4..  Anticancer vaccine formats.8
Figure 5.  Schematic of adoptive cell transfer based immunotherapies.9
Nanocarriers (NCs) have the potential to be a targeted 
delivery system for cancer therapies.
Can be targeted passively, or for specific proteins or pH 
levels.
A new form is coated with specific cancer cell proteins 
chosen for their physiological effects.11
Mechanogenetics involves bioengineering cells that directly 
affect the transcriptional activity of target cells and can be 
activated remotely within a confined tissue space such 
in/around a tumor.12
Advantages of mechanogenetics are its non-invasiveness 
and reversibility.
Control genetic activity via chemical, radio, magnetic wave, 
or ultrasound activation of elements coupled with cellular 
channels which ultimately propagate nuclear signaling 
pathways.12
Many of the mechanisms by which cancer evades the 
immune response are epigenetically regulated.
These are like tags added to DNA that can affect how much 
of areas are available for transcription.  
This tagging/untagging is carried out by two specific protein 
enzyme families. 
Pre-clinical studies have shown inhibitors of these enzymes 
can both reverse the modifications as well as improve the 
anti-tumor immune response in models of some cancer 
types.13
Potential adverse effects:  hyper immune 
response triggered toxicity including cytokine 
release syndrome, renal failure, neurotoxicity, 
and other on-target but off-tumor toxicity.11
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